echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > 8 pharmaceutical enterprises are blocked by 94 hospitals in Bengbu, and the purchase of quantity is questioned

    8 pharmaceutical enterprises are blocked by 94 hospitals in Bengbu, and the purchase of quantity is questioned

    • Last Update: 2015-04-28
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Source: in the 21st century, April 28, 2015, "volume procurement" is one of the new directions and ideas introduced in the current drug bidding, and it has also become a hot word in the pharmaceutical bidding around the world However, the volume procurement just ended in Bengbu City, Anhui Province, has caused industry controversy On April 24, the centralized volume purchase of drugs in Bengbu, Anhui Province was completed: inquiry purchase of single variety with volume, price reduction of 25% However, eight pharmaceutical enterprises, such as HongRi pharmaceutical, Baiyunshan subsidiary, Jiangsu aosaikang, GSK and so on, were not allowed to sell all their drugs in Bengbu public medical institutions permanently because the price reduction rate of drugs listed in the single variety volume purchase catalogue was not up to 25% The permanent ban on the eight companies, including Baiyunshan and other pharmaceutical companies, is considered simple and crude by insiders, which violates the principle of fairness and justice A president of a drug distribution enterprise told 21st century economic news that the above-mentioned consortium has no right to prohibit drug sales by drug enterprises, and drug enterprises are not afraid to reduce prices in practice, but only if they can actually purchase and use drugs with a volume, so as to ensure that drug enterprises do not lose money Shi lichen, head of Beijing Dingchen medical consultation center, told 21st century economic report that banning all its drugs would damage the right of local consumers to choose drugs For drugs paid by medical insurance fund, the medical insurance department should work out the payment standard of medical insurance together with relevant departments to guide the reasonable formation of market price On April 10, when eight pharmaceutical enterprises were banned, Bengbu Health Bureau issued relevant documents requiring that the profit margin of each single drug manufacturer or authorized agent in Bengbu City should not be less than 25% of the guaranteed payment price of traditional Chinese medicine in the provincial drug price limit catalogue Production enterprises can make profits directly or through the way that agents promise to make profits On April 19, a letter to pharmaceutical enterprises was issued by the pharmaceutical purchasing Consortium (hereinafter referred to as the consortium) composed of 94 public medical institutions in Bengbu City The letter clearly stipulated that if the decline of pharmaceuticals listed in the single category catalog was less than 25%, all pharmaceuticals of its manufacturers would not be sold in all public medical institutions in Bengbu permanently In addition, the above-mentioned letter also clearly indicates that for enterprises that fail to meet the standards, the consortium will report to the provincial pharmaceutical purchasing platform, apply for recording the bad behavior once, and report to the provincial medical reform office and the national medical reform office at the same time, apply for recording the bad behavior of enterprises On April 22, the official website of Bengbu Health Bureau reported the results of this centralized agent procurement According to the Bengbu health department, this procurement consortium focused on volume procurement, which was held in Bengbu public resources trading management center on April 21 After one-day review, more than 20 kinds of drugs were selected for single type volume inquiry procurement, with a 25% drop in drug price; 5 out of the city and 5 in the city, 10 distribution enterprises were selected as the winning suppliers through package competitive negotiation procurement According to Bengbu Health Bureau, from the perspective of procurement results, Bengbu basically completed the initial goal of centralized drug procurement with volume, and said that the next step would be to issue supporting documents such as measures for the supervision and implementation of centralized drug procurement with volume, so as to strengthen the supervision and management of bid winning enterprises, distribution enterprises and medical and health institutions And the previous warning of the consortium was not false On April 23, the consortium announced that the 8 enterprises, Shandong Danhong Pharmaceutical Co., Ltd., Guangzhou Baiyunshan Pharmaceutical Co., Ltd., Beijing Sihuan Pharmaceutical Co., Ltd., Harbin Songhe Pharmaceutical Co., Ltd., Jiangsu aosaikang Pharmaceutical Co., Ltd., Dali Pharmaceutical Co., Ltd., Tianjin HongRi Pharmaceutical Co., Ltd., glaxmithkline manufacturers.pa, have not reached 25% of the drugs listed in the single product catalogue As for the decline rate, all the drugs of its production enterprises shall not be sold in all the public medical institutions of Bengbu City permanently On April 27, the 21st century economic reporter called to interview the purchasing Consortium on the above issues, but the other side said that he asked "find leaders" to hang up the phone directly Subsequently, the 21st century economic news reporter called Baiyunshan secretary office, and the relevant person in charge said that the above practices were unfair to pharmaceutical companies It is a kind of market behavior that pharmaceutical companies will withdraw automatically if they are asked to reduce their prices sharply and there is no profit It is against the principle of fair competition in the market In this regard, some market analysts believe that although the price reduction is an important measure to solve the problem of high drug prices, the practice of the consortium is too rough Shi lichen told 21st century economic news that there are many doubts in the bidding process of the consortium, such as the so-called 25% price reduction rate based on what standard, and why the unqualified pharmaceutical enterprises should be permanently banned? The permanent prohibition of all the drugs of the above eight pharmaceutical companies in public hospitals has damaged the right of local consumers to choose drugs In fact, the implementation of volume purchase was questioned In fact, the "volume purchase, volume price linkage" of drugs originated in Minhang District, Shanghai Its "one product, one regulation, one factory, one distribution" drug centralized purchase mode was later used for reference by Anhui Province, and finally designed as the "one product, three dosage forms, two specifications" plus "single source commitment system" basic drug volume purchase mode On February 28, 2015, the general office of the State Council released the guiding opinions on improving the centralized drug procurement in public hospitals, which proposed the ideas of classified procurement and volume procurement The original intention of system design is: drug bidding should introduce the concept of "quantity", so as to help enterprises produce scale effect, and finally achieve the dual goals of reasonably reducing drug prices and supporting high-quality enterprises to become bigger and stronger From the current public information, Guangdong and Shanghai have carried out in-depth exploration of "volume procurement", and nearly 10 provinces and cities such as Hubei, Jiangsu and Anhui have also emphasized the implementation of "volume procurement" in some bidding documents "Purchasing with quantity" has become one of the key words in drug bidding in 2015 In the view of a president of a drug distribution enterprise, carrying quantity means the uniqueness of the batch of drug supply enterprises, which can reduce the grey space in the process of drug purchase and sale and ensure the implementation of the purchase results "In the process of bidding in Bengbu, it is still questionable whether it can really achieve volume procurement." According to the above president, pharmaceutical companies do not resist drug price reduction in fact If they can achieve volume sales and make profits at the same time, they will not do anything, but it is not easy to implement in a region or province In fact, the core of hospital prescription drug sales is doctor's prescription A person in charge of drug bidding with many years of experience explained to the 21st century economic report that it is unrealistic to determine the amount of drugs to be taken based on the sales volume of drugs in the previous year "If the products are not monopolistic, doctors have a large choice of treatment prescriptions It is possible that the price of the winning enterprise goes down, but the sales volume has not increased, and the enterprise's price reduction sales may also bring losses " In addition, it is understood that at present, the document volume reporting requirements of some provinces are based on 80% of the last year's drug consumption of the purchasing medical institutions or 20% of the fluctuation up and down The person in charge of drug bidding mentioned above points out that these up and down floating quantities are prone to errors due to poor accuracy, and it does not exclude the possibility that the medical institutions unilaterally want to reduce the purchase price and intentionally enlarge the purchase quantity Shi lichen told 21st century economic news that eight pharmaceutical companies, including HongRi pharmaceutical, Jiangsu aosaikang and GSK, are not willing to reduce the price by 25% for the drugs in the single product volume purchase catalogue, and the enterprises must have their own reasons In terms of drug characteristics, not all drugs are suitable for 25% price reduction However, if the real volume sales are realized, many enterprises may even reduce the price by 40% If drug companies are forced to reduce prices blindly, some may neglect the quality of products, and many enterprises will no longer produce low-cost drugs, which is one of the reasons why many low-cost drugs disappear in the market For example, Shi lichen said that in the past, a bottle of 100 tablets of a commonly used medicine cost only 1-2 yuan, but because the enterprise was asked to reduce the price again, it was unprofitable, so it changed the packaging At present, in the market, there is a box of 7-8 yuan, 20 tablets per box, in which there is still room for price reduction, but in fact, consumers bear more costs "For the drugs paid by medical insurance fund, the medical insurance department, together with the relevant departments, should formulate the payment standard of medical insurance, and guide the reasonable formation of market price." Shi lichen said.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.